As the drug discovery opportunity promised within the proteome becomes a reality and previously “undruggable” targets are reached, the 2nd TPD Summit  returns for 2019. This premier event exists not only to drive forward the translation of first generation of PROTACS and molecular glues into the clinic, but to  stimulate the discussion of next generation protein degraders that harness different modalities, target highly desirable targets and capitalize on degradation pathways, beyond the ubiquitin proteasome system.